Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
W
Wang, Angelia
J&J Innovative Medicine
(
M-117
)
Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment
Angelia Wang
Favorite
Wang, Bing
Amador Bioscience
(
W-132
)
Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors
Bing Wang
Favorite
Wang, Bonnie
Bristol Myers Squibb
(
M-118
)
Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety
Bonnie Wang
Favorite
(
M-119
)
Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Bonnie Wang
Favorite
Wang, Chen
ClinPharm
(
M-082
)
Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
Chen Wang
Favorite
Wang, Guanyu
Vertex Pharmaceuticals
(
T-126
)
Quantification of uncertainty in human dose predictions
Guanyu Wang
Favorite
Wang, Jin
AbbVie Inc.
(
T-127
)
Surface plasmon resonance enabled mechanistic pharmacokinetic/pharmacodynamic modeling to support covalent inhibitor drug development: Bruton’s tyrosine kinase inhibitor case study
Jin Wang
Favorite
Wang, Qi
Enliven Therapeutics
(
T-128
)
Application of PKPD Principles to Drive the Discovery and Development of Novel BCR-ABL Tyrosine Kinase Inhibitors
Qi Wang
Favorite
Wang, Yuchen
Pfizer Inc.
(
M-116
)
Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data
Yuchen Wang
Favorite
Wan, Mike
Gilead Sciences
(
W-131
)
Mechanistic modeling to inform T cell engager development for low copy targets
Mike Wan
Favorite
Wei, Tracey
(
W-049
)
Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
Tracey Wei
Favorite
Wieler, Annaliese
Metrum Research Group
(
W-012
)
Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions
Annaliese Wieler
Favorite
Wiens, Matthew
Metrum Research Group
(
W-133
)
Losing the Forest: Causal Shapley Additive Explanations for Interpretation of Population-Pharmacokinetic models
Matthew Wiens
Favorite
Woodhead, Jeff
Simulations Plus
(
M-120
)
Quantitative Systems Toxicology Modeling of Otenaproxesul Liver Enzyme Elevations Leads to Prediction of Liver Safety for Acute Otenaproxesul Dosing
Jeff Woodhead
Favorite
Woo, Laura
Bristol Myers Squibb
(
T-129
)
A prototype mechanistic systems pharmacology model of Type 2 interventions in eosinophilic esophagitis
Laura Woo
Favorite
Wu, Fan
Bristol Myers Squibb
(
M-138
)
Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
Fan Wu
Favorite
Wu, Yujie
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China
(
T-130
)
Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients
Yujie Wu
Favorite
